Author
Listed:
- Masafumi Seki
(Graduate School of Medicine, The University of Tokyo)
- Riki Nishimura
(Graduate School of Medicine, The University of Tokyo)
- Kenichi Yoshida
(Graduate School of Medicine, Kyoto University
Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo)
- Teppei Shimamura
(Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
Nagoya University Graduate School of Medicine)
- Yuichi Shiraishi
(Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo)
- Yusuke Sato
(Graduate School of Medicine, Kyoto University
Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo)
- Motohiro Kato
(Graduate School of Medicine, The University of Tokyo
The University of Tokyo
Saitama Children’s Medical Center)
- Kenichi Chiba
(Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo)
- Hiroko Tanaka
(Laboratory of Sequence Data Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo)
- Noriko Hoshino
(Graduate School of Medicine, The University of Tokyo)
- Genta Nagae
(Research Center for Advanced Science and Technology, The University of Tokyo)
- Yusuke Shiozawa
(Graduate School of Medicine, Kyoto University
Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo)
- Yusuke Okuno
(Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo
Nagoya University Graduate School of Medicine)
- Hajime Hosoi
(Kyoto Prefectural University of Medicine, Graduate School of Medical Science)
- Yukichi Tanaka
(Kanagawa Children's Medical Center)
- Hajime Okita
(Molecular Pathology Laboratory, National Research Institute for Child Health and Development)
- Mitsuru Miyachi
(Kyoto Prefectural University of Medicine, Graduate School of Medical Science)
- Ryota Souzaki
(Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University)
- Tomoaki Taguchi
(Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University)
- Katsuyoshi Koh
(Saitama Children’s Medical Center)
- Ryoji Hanada
(Saitama Children’s Medical Center)
- Keisuke Kato
(Ibaraki Children’s Hospital)
- Yuko Nomura
(School of Medicine, Fukuoka University)
- Masaharu Akiyama
(The Jikei University School of Medicine)
- Akira Oka
(Graduate School of Medicine, The University of Tokyo)
- Takashi Igarashi
(Graduate School of Medicine, The University of Tokyo
National Center for Child Health and Development)
- Satoru Miyano
(Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
Laboratory of Sequence Data Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo)
- Hiroyuki Aburatani
(Research Center for Advanced Science and Technology, The University of Tokyo)
- Yasuhide Hayashi
(Gunma Children's Medical Center)
- Seishi Ogawa
(Graduate School of Medicine, Kyoto University
Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo)
- Junko Takita
(Graduate School of Medicine, The University of Tokyo)
Abstract
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in childhood. Here we studied 60 RMSs using whole-exome/-transcriptome sequencing, copy number (CN) and DNA methylome analyses to unravel the genetic/epigenetic basis of RMS. On the basis of methylation patterns, RMS is clustered into four distinct subtypes, which exhibits remarkable correlation with mutation/CN profiles, histological phenotypes and clinical behaviours. A1 and A2 subtypes, especially A1, largely correspond to alveolar histology with frequent PAX3/7 fusions and alterations in cell cycle regulators. In contrast, mostly showing embryonal histology, both E1 and E2 subtypes are characterized by high frequency of CN alterations and/or allelic imbalances, FGFR4/RAS/AKT pathway mutations and PTEN mutations/methylation and in E2, also by p53 inactivation. Despite the better prognosis of embryonal RMS, patients in the E2 are likely to have a poor prognosis. Our results highlight the close relationships of the methylation status and gene mutations with the biological behaviour in RMS.
Suggested Citation
Masafumi Seki & Riki Nishimura & Kenichi Yoshida & Teppei Shimamura & Yuichi Shiraishi & Yusuke Sato & Motohiro Kato & Kenichi Chiba & Hiroko Tanaka & Noriko Hoshino & Genta Nagae & Yusuke Shiozawa & , 2015.
"Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma,"
Nature Communications, Nature, vol. 6(1), pages 1-8, November.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8557
DOI: 10.1038/ncomms8557
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8557. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.